Biohaven Pharma (BHVN) Misses Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts BHVN Hot Sheet
Join SI Premium – FREE
Biohaven Pharma (NYSE: BHVN) reported Q2 EPS of ($0.78), $0.03 worse than the analyst estimate of ($0.75).
For earnings history and earnings-related data on Biohaven Pharma (BHVN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RBC Capital on Compass Pathways (CMPS): 'We See an Opportunity to Buy on Weakness'
- CPS Technologies (CPSH) Reports In-Line Q3 EPS
- Credit Acceptance ALERT: Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
